Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study

Keyphrases

• Newly Diagnosed 100%
• Hodgkin Lymphoma 100%
• Dose-escalation Study 100%
• Brentuximab Vedotin 100%
• Toxic Effects 18%
• Maximum Tolerated Dose 13%
• Safety Profile 13%
• Bleomycin 13%
• Febrile Neutropenia 9%
• Serious Events 9%
• Treatment-naïve 9%
• Advanced-stage Hodgkin Lymphoma 9%
• First-line Therapy 4%
• Dyspnea 4%
• Adverse Events 4%
• Dose Escalation 4%
• Doxorubicin 4%
• Stem Cell Transplantation 4%
• Phase II Trial 4%
• Clinical Activity 4%
• Syncope 4%
• Intravenous Infusion 4%
• Number of Patients 4%
• Safety Study 4%
• Relapsed or Refractory 4%
• Anemia 4%
• Second-line Treatment 4%
• Relapsed Lymphoma 4%
• Modified Treatment 4%
• Previously Untreated 4%
• Complete Remission 4%
• One Dose 4%
• Leukopenia 4%
• Neutropenia 4%
• Pulmonary Embolism 4%
• Seattle 4%
• Entry Criteria 4%
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 4%
• Received Dose 4%
• Treatment-naïve Patients 4%
• Vinblastine 4%
• Stage IA2 4%
• Bulky Disease 4%
• Early Efficacy 4%
• Dacarbazine 4%
• CD30 Positive 4%
• Refractory Hodgkin Lymphoma 4%
• Main Entry 4%
• Historical Incidence 4%
• BEACOPP 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Hodgkin Disease 100%
• Brentuximab Vedotin 100%
• Maximum Tolerated Dose 13%
• Bleomycin 13%
• Febrile Neutropenia 9%
• Diseases 9%
• Adverse Event 4%
• Doxorubicin 4%
• Dyspnea 4%
• Remission 4%
• Anemia 4%
• Neutropenia 4%
• Leukopenia 4%
• Lung Embolism 4%
• Faintness 4%
• Vinblastine 4%
• Dacarbazine 4%